Tocilizumab for Acute Chest Syndrome
Phase 2
200
about 3.8 years
12+
1 site in IL
What this study is about
This trial is testing if a low dose of tocilizumab, a medication that blocks interleukin-6 (IL-6), can help treat acute chest syndrome in people with sickle cell disease. The goal is to see how this treatment affects oxygen levels, clinical outcomes, and lab results for patients hospitalized with acute chest syndrome.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Tocilizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
tocilizumab (Monoclonal antibody; blocks IL-6 receptor to reduce inflammation)
infusion
Secondary: Length of stay, Mortality rate, Readmission rate